HUTCHMED (ADR)
Develops targeted therapies and immunotherapies, commercializing medicines in China and through global partners.
$12.31
After-hours close−0.06 (−0.49%)
At close$12.37(−0.36%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Jul 2026 | $0.15 | $0.05 | −68.3% |
| Jul 2026 | −$0.36 | — | — |
| Jun 2026 | −$0.36 | — | — |
| Jun 2026 | −$0.36 | — | — |
| Jun 2026 | −$0.36 | — | — |
| Jun 2026 | −$0.36 | — | — |
| Mar 2026 | $2.50 | — | — |
| Aug 2025 | $1.46 | $1.30 | −11.0% |
| Jul 2025 | — | $1.30 | — |
The latest year is open to everyone — the 37 quarters behind it read with an account. Sign in | |||
| Mar 2025 | |||
| Sep 2024 | |||
| Jul 2024 | |||
| Jun 2024 | |||
| Feb 2024 | |||
| Jul 2023 | |||
| Jun 2023 | |||
| Feb 2023 | |||
| Aug 2022 | |||
| Sep 2021 | |||
| Jul 2021 | |||
| Sep 2020 | |||
| Jul 2020 | |||
| Mar 2020 | |||
| Sep 2019 | |||
| Mar 2019 | |||
| Sep 2018 | |||
| Mar 2018 | |||
| Mar 2018 | |||
| Mar 2017 | |||
| Mar 2017 | |||
| Sep 2016 | |||
| Mar 2016 | |||
| Mar 2016 | |||
| Sep 2015 | |||
| Jun 2015 | |||
| Mar 2015 | |||
| Dec 2014 | |||
| Sep 2014 | |||
| Jun 2014 | |||
| Mar 2014 | |||
| Dec 2013 | |||
| Sep 2013 | |||
| Jun 2013 | |||
| Mar 2013 | |||
| Dec 2012 | |||
| Sep 2012 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | $0.15 | $0.05 | −68.3% | $304.2M | $278.3M | −8.5% |
| Jul 2, 2026 | −$0.36 | — | — | $80.9M | — | — |
| Jun 25, 2026 | −$0.36 | — | — | $80.9M | — | — |
| Jun 18, 2026 | −$0.36 | — | — | $80.9M | — | — |
| Jun 11, 2026 | −$0.36 | — | — | $80.9M | — | — |
| Jun 4, 2026 | −$0.36 | — | — | $80.9M | — | — |
| Mar 5, 2026 | $2.50 | — | — | $290.5M | $271.0M | −6.7% |
| Aug 7, 2025 | $1.46 | $1.30 | −11.0% | $330.4M | $138.8M | −58.0% |
| Jul 2, 2025 | — | $1.30 | — | — | $138.8M | — |
The latest year is open to everyone — the 37 quarters behind it read with an account. Sign in | ||||||
| Mar 19, 2025 | ||||||
| Sep 30, 2024 | ||||||
| Jul 31, 2024 | ||||||
| Jun 10, 2024 | ||||||
| Feb 28, 2024 | ||||||
| Jul 31, 2023 | ||||||
| Jun 20, 2023 | ||||||
| Feb 28, 2023 | ||||||
| Aug 1, 2022 | ||||||
| Sep 30, 2021 | ||||||
| Jul 28, 2021 | ||||||
| Sep 30, 2020 | ||||||
| Jul 30, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Sep 30, 2019 | ||||||
| Mar 31, 2019 | ||||||
| Sep 30, 2018 | ||||||
| Mar 31, 2018 | ||||||
| Mar 12, 2018 | ||||||
| Mar 31, 2017 | ||||||
| Mar 14, 2017 | ||||||
| Sep 30, 2016 | ||||||
| Mar 31, 2016 | ||||||
| Mar 1, 2016 | ||||||
| Sep 30, 2015 | ||||||
| Jun 30, 2015 | ||||||
| Mar 31, 2015 | ||||||
| Dec 31, 2014 | ||||||
| Sep 30, 2014 | ||||||
| Jun 30, 2014 | ||||||
| Mar 31, 2014 | ||||||
| Dec 31, 2013 | ||||||
| Sep 30, 2013 | ||||||
| Jun 30, 2013 | ||||||
| Mar 31, 2013 | ||||||
| Dec 31, 2012 | ||||||
| Sep 30, 2012 | ||||||